Drug intelligence / Profile preview

osimertinib + sapanisertib

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of osimertinib, an EGFR tyrosine kinase inhibitor, and sapanisertib, an oral mTOR inhibitor that targets both mTORC1 and mTORC2 complexes. This combination is being investigated primarily for the treatment of osimertinib-resistant EGFR-mutated non-small cell lung cancer (NSCLC). The scientific rationale for this combination stems from evidence that the mTOR pathway is implicated in resistance to EGFR inhibitors like osimertinib.

Other names: MLN0128MLN-0128MLN 0128INK128INK-128INK 128TAK-228TAK228TAK 228

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2

Beyond the preview

Go deeper on osimertinib + sapanisertib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on osimertinib + sapanisertib.

Explore the full profile